Tech Company Financing Transactions
Cleveland Diagnostics Funding Round
Cleveland Diagnostics secured a $75 million venture capital round on 1/17/2024. Backers included Novo Holdings and Symbiotic Capital.
Transaction Overview
Company Name
Announced On
1/17/2024
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Undisclosed
Investors
Novo Holdings (Lead Investor)
Proceeds Purpose
Proceeds will accelerate the commercial strategy of IsoPSA, fund expanded infrastructure and R&D pipeline development, and broaden the geographic scope of its novel IsoPSA prostate cancer test.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
3615 Superior Ave. 4407B
Cleveland, OH 44114
USA
Cleveland, OH 44114
USA
Phone
Website
Email Address
Overview
Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers -- early on, when cancer is still curable.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arnon Chait
Chief Medical Officer
Mark Stovsky
Chief Operating Officer
Aimee Kestranek
Chief Scientific Officer
Boris Zaslavsky
VP - Bus. Development
Robert Rochelle
VP - Finance
Michael Halliburton
Browse more venture capital transactions:
Prev: 1/17/2024: AccessParks venture capital transaction
Next: 1/18/2024: Flowdesk venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs